Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Leukemia, Monocytic, Acute

ClinicalTrials.gov lists 193 trials for Leukemia, Monocytic, Acute or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 44.

MeSH D007948 Neoplasms Neoplasm C04 C15 Listed by Orphanet as a rare disease
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 55 Phase 1/2 Phase 1/2 12 Phase 2 Phase 2 77 Phase 2/3 Phase 2/3 3 Phase 3 Phase 3 22 Not applicable Not applicable 8 Observational Observational 15 Expanded access Expanded access 1 Phase 1 Phase 1 55 Phase 1/2 Phase 1/2 12 Phase 2 Phase 2 77 Phase 2/3 Phase 2/3 3 Phase 3 Phase 3 22 Not applicable Not applicable 8 Observational Observational 15 Expanded access Expanded access 1

Trials per phase (log scale)

193 of the 193 trials are tagged with Leukemia, Monocytic, Acute itself; the rest are tagged with a narrower condition beneath it.

Get the Leukemia, Monocytic, Acute report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Leukemia, Monocytic, Acute trials start? (32)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Not applicable
  • Observational
  • Expanded access

Top of scale: 18

1993: 1 trials (Phase 3 1) 1994: 4 trials (Phase 3 1, Phase 2 2, Phase 1 1) 1995: 1 trials (Phase 3 1) 1996: 2 trials (Phase 3 1, Phase 2 1) 1997: 1 trials (Phase 1/2 1) 1998: 8 trials (Phase 3 3, Phase 2 2, Phase 1 3) 1999: 9 trials (Phase 3 1, Phase 2 4, Phase 1/2 1, Phase 1 3) 2000: 10 trials (Phase 3 3, Phase 2 7) 2001: 4 trials (Not applicable 1, Phase 2 3) 2002: 5 trials (Phase 3 2, Phase 2 1, Phase 1 2) 2003: 3 trials (Phase 2 1, Phase 1 2) 2004: 16 trials (Phase 3 2, Phase 2/3 1, Phase 2 6, Phase 1/2 1, Phase 1 6) 2005: 14 trials (Phase 3 3, Phase 2 1, Phase 1 10) 2006: 14 trials (Observational 3, Not applicable 1, Phase 3 1, Phase 2/3 1, Phase 2 6, Phase 1 2) 2007: 8 trials (Expanded access 1, Phase 2 2, Phase 1/2 2, Phase 1 3) 2008: 18 trials (Observational 2, Not applicable 1, Phase 3 1, Phase 2 10, Phase 1/2 2, Phase 1 2) 2009: 6 trials (Observational 1, Phase 2 2, Phase 1/2 2, Phase 1 1) 2010: 10 trials (Observational 2, Phase 2 4, Phase 1 4) 2011: 14 trials (Observational 5, Phase 3 2, Phase 2 5, Phase 1/2 1, Phase 1 1) 2012: 5 trials (Observational 2, Phase 2 1, Phase 1 2) 2013: 7 trials (Not applicable 2, Phase 2 2, Phase 1 3) 2014: 7 trials (Not applicable 1, Phase 2 4, Phase 1 2) 2015: 2 trials (Phase 1 2) 2016: 1 trials (Phase 1 1) 2018: 2 trials (Phase 2 2) 2019: 2 trials (Phase 2 1, Phase 1/2 1) 2020: 4 trials (Phase 2 3, Phase 1 1) 2021: 4 trials (Phase 2/3 1, Phase 2 1, Phase 1 2) 2022: 2 trials (Phase 2 1, Phase 1/2 1) 2024: 2 trials (Not applicable 1, Phase 1 1) 2025: 3 trials (Phase 2 2, Phase 1 1)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 1
2025 3
2024 2
2022 2
2021 4
2020 4
2019 2
2018 2
2016 1
2015 2

Showing 10 of 32 earlier years.

Start your 14-day trial Email me all 32 earlier years as a PDF

No forecast is made for this condition: it averages 2.0 trial starts a year over the five years to September, under the 5 a year the method needs.

Prediction, not a registry value: median of 36 months from start to primary completion across 9 trials still running at the 2026-10-09 snapshot; registered median of 45 months across 155 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Leukemia, Monocytic, Acute trials in? (8)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 55
Phase 1/2 12
Phase 2 77
Phase 2/3 3
Phase 3 22
Not applicable 8
Observational 15
Expanded access 1

How many Leukemia, Monocytic, Acute trials are recruiting? (7)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Recruiting 10
Active, not recruiting 4
Completed 130
Terminated 28
Withdrawn 4

Showing 5 of 7 statuses.

Start your 14-day trial Email me all 7 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Leukemia, Monocytic, Acute trials? (6)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Cancer Institute (NCI) 44
SWOG Cancer Research Network 11
European Organisation for Research and Treatment of Cancer - EORTC 8
Eastern Cooperative Oncology Group 6
Children's Oncology Group 5

Showing 5 of 6 sponsors.

Start your 14-day trial Email me all 6 sponsors as a PDF

Which drugs are being tested for Leukemia, Monocytic, Acute? (4)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Mitoxantrone 26
Busulfan 20
Cytoxan 17
Tipifarnib 11

Interventions as named in the registry (11)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Cytarabine IT 83
Etoposid 31
Daunorubicine 28
Idarubicina 26
Filgrastime (G-CSF) 23

Showing 5 of 11 interventions.

Start your 14-day trial Email me all 11 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Leukemia, Monocytic, Acute trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Platelet count decreased 1,530 9
Neutrophil count decreased 1,486 11
Anemia 1,406 8
White blood cell decreased 1,202 6
Febrile neutropenia 924 22

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Leukemia, Monocytic, Acute? (11)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Prognostic stratification of molecularly and clinically distinct subgroup in children with acute monocytic leukemia. Cancer medicine 2020 Yes
Retinoic acid receptor-β gene reexpression and biological activity in SHI-1 cells after combined treatment with 5-aza-2'-deoxycytidine and all-trans retinoic acid. Acta haematologica 2015 Yes
Two dosing regimens of tosedostat in elderly patients with relapsed or refractory acute myeloid leukaemia (OPAL): a randomised open-label phase 2 study. The Lancet. Oncology 2013 Yes
Head and neck granulocytic sarcoma with acute myeloid leukemia: three rare cases. Ear, nose, & throat journal 2001 Yes
Donor leucocyte infusions after chemotherapy for patients relapsing with acute leukaemia following allogeneic BMT. Bone marrow transplantation 1993 Yes

Showing 5 of 11 publications.

Start your 14-day trial Email me all 11 publications as a PDF

Prevalence (6)

Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.

Prevalence
Orphanet disease Type Class Geography Jurisdiction Mapping relation
Acute monoblastic/monocytic leukemia Point prevalence 1-9 / 1 000 000 Europe Not stated Exact
Acute monoblastic/monocytic leukemia Annual incidence 1-9 / 1 000 000 Europe Not stated Unspecified
Acute monoblastic/monocytic leukemia Annual incidence 1-9 / 1 000 000 Europe Not stated Exact
Acute monoblastic/monocytic leukemia Point prevalence 1-9 / 1 000 000 Europe Not stated Exact
Acute monoblastic/monocytic leukemia Annual incidence 1-9 / 1 000 000 Europe Not stated Exact

Showing 5 of 6 prevalence observations.

Start your 14-day trial Email me all 6 prevalence observations as a PDF

Rare-disease identity (2)

Shown in this order: exact, broader, narrower, other.

Rare-disease identity
Orphanet disease ORPHA code Relation Source
Acute monoblastic/monocytic leukemia 514 Exact Orphanet Rare Disease Ontology (ORDO)
Acute monoblastic/monocytic leukemia 514 Exact Orphadata Science knowledge files, Product 1

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: sub-conditions in mesh.

Browse all condition evidence pages